Biotech company Moderna, which is conducting a late-stage trial for its experimental COVID-19 vaccine candidate, said it won’t enforce any patents related to its work for the duration of the pandemic.
The Massachusetts-based company said in an Oct. 8 statement that it “feels a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible” and won’t enforce its COVID-19-related rights against vaccine makers using its product to fight the CCP (Chinese Communist Party) virus outbreak.
